Results 61 to 70 of about 5,464 (192)

Biomimetic Cell Membrane‐Coated Scaffolds for Enhanced Tissue Regeneration

Advanced Materials, Volume 37, Issue 40, October 9, 2025.
This review examines the development and use of cell membrane‐coated scaffolds in tissue engineering. Bioinspired phospholipid and glycocalyx coatings enhance anti‐fouling, anti‐thrombogenic, and selective molecular recognition properties. Native cell membrane coatings further support cell‐specific interactions, immune modulation, and reduced bacterial
Carmen Alvarez‐Lorenzo, Alejandro Ramirez‐Romero, Diana Peixoto, Maria Vivero‐Lopez, Isabel Rodríguez‐Moldes, Angel Concheiro   +5 more
wiley   +1 more source

Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review

Catheterization and Cardiovascular Interventions, Volume 106, Issue 3, Page 2037-2047, September 1, 2025.
ABSTRACT The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter‐atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy.
Eirini Beneki, Kyriakos Dimitriadis, Nikolaos Pyrpyris, Georgios Tzimas, Ioannis Skalidis, David Meier, Panagiotis Antiochos, Panagiotis Kostakis, Efthymia Pavlou, Francesco Perone, Georgios Tsivgoulis, Constantina Aggeli, Ole de Backer, Konstantinos Tsioufis   +13 more
wiley   +1 more source

Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.

, 2004
CONTEXT: The optimal pharmacological strategy for bridging the delay between admission and performance of percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (MI) is not known.
Kastrati, A;Mehilli, J;Schlotterbeck, K;Dotzer, F;Dirschinger, J;Schmitt, C;Nekolla, SG;Seyfarth, M;Martinoff, S;Markwardt, C;Clermont, G;Gerbig, HW;Leiss, J;Schwaiger, M;Schömig, A
core   +1 more source

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 470-479, August 2025.
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Ashley N. Springer, Leah A. Alicea, Yemi Gafari, Tayler B. Smith, Sheryl Lynch, Amy M. Breman, Jennelle C. Hodge, Victoria M. Pratt, Nicholas R. Powell, Rolf P. Kreutz, Daniel P. Kobold, Michael T. Eadon, Emma M. Tillman, Tyler Shugg, Todd C. Skaar   +14 more
wiley   +1 more source

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj  

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells

Cardiovascular Diabetology, 2008
Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Huang Jianhua, Zhao Renyi, Pathak Alokkumar, Stouffer George A   +3 more
doaj   +1 more source

Abciximab for thrombolysis during intracranial aneurysm coiling [PDF]

, 2018
Introduction: Thrombotic events are a common and severe complication of endovascular aneurysm treatment with significant impact on patients' outcome.
Lalloo, Shivendra, Kuker, Wilhem, Molyneux, Andrew, Gralla, Jan, Corkill, Rufus, Byrne, James, Rennie, Adam   +6 more
core  

Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial)

Current Controlled Trials in Cardiovascular Medicine, 2004
Background Although percutaneous coronary intervention (PCI) is becoming the standard therapy in ST-segment elevation myocardial infarction (STEMI), to date most patients, even in developed countries, are reperfused with intravenous thrombolysis or do ...
Visser Cees A, Bronzwaer Jean GF, Kamp Otto, Veen Gerrit, van Loon Ramon B, Visser Frans C   +5 more
doaj   +1 more source

The FRED‐X Flow Diverter—An Australian Experience

Journal of Medical Imaging and Radiation Oncology, Volume 69, Issue 4, Page 484-490, June 2025.
ABSTRACT Background The FRED X flow diverter features antithrombotic surface treatment to reduce thrombogenicity. This study evaluated the safety and efficacy of FRED X in treating intracranial aneurysms in the Australian setting. Methods Clinical, procedural and imaging data were retrospectively reviewed for a consecutive series of patients at a ...
Peter Shuangyue Tan, Charles Li, Cameron Williams, Winston Chong, Carlos Chung, Conor Houlihan, Anoop Madan   +6 more
wiley   +1 more source

Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban

Кардиоваскулярная терапия и профилактика, 2008
The review presents literature data on the key role of platelet aggregation (PA) for intracoronary thrombogenesis in various acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).
T. A. Batyraliev, D. V. Preobrazhensky, D. V. Fetzer, B. A. Sidorenko, S. A. Pataraya   +4 more
doaj